Literature DB >> 16547761

[Cutaneous lupus erythematosus. Part 2: diagnostics and therapy].

A Kuhn1, K Gensch, S Ständer, G Bonsmann.   

Abstract

The diagnosis of cutaneous lupus erythematosus (CLE) requires a specific diagnostic approach to identify subtypes, to address differential diagnostic considerations, and to rule out systemic organ involvement. In addition to a detailed patient's history and clinical evaluation of the skin, histopathologic and immunofluorescent examination of a skin biopsy as well as laboratory screening are recommended. Photoprovocation tests can be performed to confirm the diagnosis of CLE and to assess photosensitivity in these patients. Recently, a scoring system for the activity of the cutaneous manifestations in CLE has been developed and validated which involves anatomical areas and morphologic signs of the skin lesions. In all subtypes of CLE, antimalarials are still the treatment of choice. Advances in biotechnology have led to the development of several novel agents for the treatment of autoimmune diseases; however, controlled trials have not been performed in patients with CLE. Furthermore, there is need for specific immunointervention, especially for patients who fail to respond to standard therapies. The second part of this review will enable the reader to differentiate CLE from other diseases and to suggest specific diagnostic procedures and treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547761     DOI: 10.1007/s00105-006-1138-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  67 in total

1.  Phototesting in lupus erythematosus: a 15-year experience.

Authors:  A Kuhn; M Sonntag; D Richter-Hintz; C Oslislo; M Megahed; T Ruzicka; P Lehmann
Journal:  J Am Acad Dermatol       Date:  2001-07       Impact factor: 11.527

2.  [Topical treatment with tacrolimus in lupus erythematosus tumidus].

Authors:  D Bacman; A Tanbajewa; M Megahed; T Ruzicka; A Kuhn
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

3.  Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.

Authors:  M L Jewell; D P McCauliffe
Journal:  J Am Acad Dermatol       Date:  2000-06       Impact factor: 11.527

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

Review 5.  Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus.

Authors:  K M David-Bajar; B M Davis
Journal:  Lupus       Date:  1997       Impact factor: 2.911

Review 6.  Cutaneous lupus erythematosus.

Authors:  D P McCauliffe
Journal:  Semin Cutan Med Surg       Date:  2001-03

7.  Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil.

Authors:  C N Pisoni; G Obermoser; M J Cuadrado; F J Sanchez; Y Karim; N T Sepp; M A Khamashta; G R V Hughes
Journal:  Clin Exp Rheumatol       Date:  2005 May-Jun       Impact factor: 4.473

8.  Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus.

Authors:  T Kanekura; N Yoshii; K Terasaki; H Miyoshi; T Kanzaki
Journal:  Br J Dermatol       Date:  2003-02       Impact factor: 9.302

9.  Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.

Authors:  Michelle T Pelle; Jeffrey P Callen
Journal:  Arch Dermatol       Date:  2002-09

10.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Authors:  Martin Aringer; Winfried B Graninger; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2004-10
View more
  1 in total

Review 1.  [Dermatological symptoms in rheumatology].

Authors:  E Aberer
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.